Showing: 1 - 2 of 2 RESULTS

Jennifer Kocour Named Chief Operating Officer of CCT Research as Company Continues U.S. Expansion

An experienced clinical research leader, Kocour will oversee business operations and strategic growth for the CCT Network of Sites

CCT Research, a company offering an innovative approach to conducting clinical trials for the prevention and treatment of debilitating diseases, announced today that Jennifer Kocour has joined the company as its Chief Operating Officer. Kocour brings a wealth of industry experience, having started her career as a Clinical Research Assistant before advancing to roles as a Site Coordinator, Regional Manager, Clinical Team Lead, and Vice President of Operations.

Kocour’s appointment comes as CCT Research continues to rapidly expand its geographic and therapeutic reach since opening its doors in 2017. “I’m excited to join a company that’s dedicated to industry innovation, exceptional patient care, and the growth and development of our staff as we continue to grow as a company,” said Kocour.

CCT Research currently has 17 sites across Arizona, Nebraska, and Utah. The sites are located in physicians’ offices, medical clinics, and senior living communities; and the company is looking to add partner sites in new markets. By embedding its clinical research infrastructure and staff into these facilities, CCT Research provides convenient and comfortable study locations for qualified patients in a variety of therapeutic areas. Recently, the company was selected to partner with several top pharmaceutical companies to conduct trials for a COVID-19 vaccine.

“Strong leadership is key to supporting these critical study efforts and future medical research,” said CJ Anderson, President of CCT Research. “Jennifer is a proven leader, and her diverse background provides an understanding of each individual’s role in conducting a successful clinical trial. We’re happy to have her as the newest member of our executive leadership team.”

About CCT Research

CCT Research is a company offering an innovative approach to conducting clinical trials for the prevention and treatment of debilitating diseases. CCT’s research sites are located within physicians’ offices, medical clinics, and senior living communities to support research in the fields of Neurology, Family Practice, and Dermatology, with plans to include additional therapy areas in the near future. The company’s unique model simplifies the process for trial participants and provides pharmaceutical sponsors with high quality data. For more information, visit cctresearch.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005945/en/

Contacts

CJ Anderson, President
CCT Research
480-702-3501
[email protected]

Source Article

Schwazze, Formerly Operating as Medicine Man Technologies, Inc., Provides Update on Acquisition Strategy

DENVER–(BUSINESS WIRE)–Sep 30, 2020–

Schwazze, formerly operating as Medicine Man Technologies Inc. (OTCQX: SHWZ) (“Schwazze ” or “the Company”), a leading vertically-integrated Colorado cannabis company, today provided an update on its acquisition strategy.

The Company announced the termination of previously named term sheet with MedPharm Holdings, a cannabis research and development operator, which expired today, September 30, 2020. As noted earlier this year, the Company had moved forward on numerous term sheets with Colorado cannabis operators but had completed limited due diligence at that time. After the rigorous review and vetting process of MedPharm, the Company was unable to reach a mutually beneficial agreement to acquire MedPharm.

Justin Dye, Chairman and Chief Executive Officer of Schwazze shared, “The decision to terminate the binding term sheet with MedPharm is the right step forward for Schwazze. We are committed to creating shareholder value and generating compelling investment returns and believe that by staying true to our core business strategy of building a vertically integrated platform, we will do just that. Our focus remains unchanged, as our intention is to bring together profitable cannabis operators while growing organically to create a robust, differentiated and most admired cannabis company.”

Schwazze reiterated its commitment to establishing a leading vertically integrated cannabis platform. To accomplish this, the Company has acquired Mesa Organics, a dispensary chain with four locations in Southern Colorado, Purplebee’s a leading extraction and manufacturing business and remains on track to acquire the 14 Colorado locations of Star Buds which includes 13 retail locations and a cultivation facility. The Company will continue to make decisions that uniquely position Schwazze to provide the most trusted products and experiences for consumers and the best value for shareholders. The Company remains in negotiations with the announced acquisitions Roots Rx and Canyon Cultivation.

For more information about Schwazze, please visit https://www.Schwazze.com/.

About Schwazze

Medicine Man Technologies, Inc. is now operating under its new trade name, Schwazze. Schwazze (OTCQX: SHWZ) is executing its vision to become a leading vertically integrated cannabis holding company with a portfolio consisting of top-tier licensed brands spanning cultivation, extraction, infused-product manufacturing, dispensary operations, consulting, and a nutrient line. Schwazze leadership includes Colorado cannabis leaders with proven expertise in product and business development as well as top-tier executives from Fortune 500 companies. As a leading platform for vertical integration, Schwazze is strengthening the operational efficiency of the cannabis industry in Colorado and beyond, promoting sustainable growth and increased access to capital, while delivering best-quality service and products to the end consumer. The corporate entity continues to be named Medicine Man Technologies, Inc.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual